CHF Device Trial Endpoints Clarification From FDA Requested

This article was originally published in The Gray Sheet

15 Apr 2002
News

Executive Summary

Thoratec's REMATCH trial of the HeartMate VE left ventricular assist device, designed to demonstrate improved survival versus optimal medical management, will not be generalizable to most congestive heart failure device trials, according to Mehmet Oz, MD, Columbia University

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT016404

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT016404

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

CHF Device Trial Endpoints Clarification From FDA Requested

News

Executive Summary

Related Content

Who’s In Control? Thoratec, Investigators Discuss Access To NIH-Funded Data

Who’s In Control? Thoratec, Investigators Discuss Access To NIH-Funded Data

Arrow LionHeart

Arrow LionHeart

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert